Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

ctDNA a Viable Surrogate for OS in Previously Treated Metastatic Uveal Melanoma

September 19th 2021

Circulating tumor DNA was a better predictor for survival than RECIST 1.1 for patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma assigned to tebentafusp.

Adjuvant Pembrolizumab Induces RFS Benefit in Resected High-Risk Stage II Melanoma

September 18th 2021

Adjuvant pembrolizumab led to a significant reduction in the risk of disease recurrence or death compared with placebo in patients with resected, high-risk stage II melanoma.

Dr. Janku on the Efficacy of Ripretinib in KIT-Mutated Melanoma

September 17th 2021

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

The Hamilton of Medicine

September 3rd 2021

Most physician-scientists are intense, motivated and focused, but Keith T. Flaherty, MD, takes it to another level.

UV1 Vaccine Plus Pembrolizumab Shows Strong Safety, Early Activity in Metastatic Melanoma

September 2nd 2021

The universal cancer vaccine UV1 and granulocyte-macrophage colony-stimulating factor in combination with pembrolizumab elicited encouraging initial signs of clinical response with favorable safety and tolerability when used in the first-line treatment of patients with metastatic melanoma, meeting the primary end point of an ongoing phase 1 trial.

Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma

September 1st 2021

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

Prior Treatment Confers Reduced Responses With Adoptive Transfer of TIL Therapy in Metastatic Melanoma

August 26th 2021

Prior treatment with PD-1 or MAPK inhibitors resulted in lower objective response rates with adoptive cell transfer of autologous tumor-infiltrating lymphocytes in patients with metastatic melanoma vs patients who were naïve to these agents.

FDA and EMA Accept Tebentafusp Applications for Metastatic Uveal Melanoma

August 24th 2021

The FDA and the European Medicines Agency have accepted applications seeking the approval of tebentafusp for use in the treatment of adult patients with HLA-A*02:01–positive metastatic uveal melanoma.

Clinicopathologic and Genomic Testing Confirm Differences in Pediatric Melanocytic Tumors

August 24th 2021

Distinct subgroups of pediatric melanocytic lesions, which were identified by an integrated clinicopathologic and genomic analysis, were found to have different clinical behaviors, suggesting that this combined diagnostic modality could inform individualized diagnoses and treatments for patients with these rare malignancies.

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

August 20th 2021

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting

August 5th 2021

Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.

FDA Grants Priority Review to Adjuvant Pembrolizumab for Stage II High-Risk Melanoma

August 5th 2021

The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

Future Management of Uveal Melanoma

August 2nd 2021

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.

Uveal Melanoma: Patient Candidacy for Tebentafusp

August 2nd 2021

Drs Richard D. Carvajal and Marlana M. Orloff highlight variables that should be considered when assessing the appropriateness for treating patients with uveal melanoma with tebentafusp.

Tebentafusp for Uveal Melanoma: Cytokine Release Syndrome

August 2nd 2021

Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.

Tebentafusp for Uveal Melanoma: Adverse Events

August 2nd 2021

What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.

Uveal Melanoma: Sequencing Therapy

August 2nd 2021

Potential sequencing strategies with novel therapies such as tebentafusp for uveal melanoma.

FDA Grants Fast Track Status to Nemvaleukin Alfa for Mucosal Melanoma

August 2nd 2021

The FDA has granted a fast track designation to nemvaleukin alfa as a potential therapeutic option for patients with mucosal melanoma.

Tebentafusp for Uveal Melanoma: Assessing Treatment Response

July 23rd 2021

Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.